Astellas has announced that it will be acquiring Audentes Therapeutics at a total cost of $3 billion.
List view / Grid view
Rachael Harper (European Pharmaceutical Review)
Filter the results
Scientists have proposed combining ultrasound with other techniques to improve drug transport into brain tumours.
A medicinal CBD oil has been approved for importation, prescription and supply under the Medical Cannabis Access Programme (MCAP) in Ireland.
A week-long awareness-raising campaign has been launched to combat the spread of substandard and falsified medicines.
The FDA has granted early-action approval to Exservan for the treatment of ALS, which can be administered safely and easily without water.
A warning letter has been issued by the FDA for products illegally marketed for the treatment of health conditions, including opioid withdrawal symptoms.
A new technique has been demonstrated that will control the size and shape of nanoparticles which could lead to their use as a form of drug delivery.
Remsima SC™ is the world’s first subcutaneous formulation of infliximab and has been approved in the EU for the treatment of people with rheumatoid arthritis.
Four companies are recalling batches of certain over-the-counter ranitidine medicines used to treat conditions such as stomach ulcers and heartburn.
The investigational broadly neutralising antibody, N6LS, is to be developed by ViiV Healthcare for the treatment and prevention of HIV-1.
The preference for orally disintegrating tablets (ODT) to treat CNS-related diseases will increase the market from $12bn in 2018, with a solid growth rate.
Givlaari (givosiran) has been approved by the FDA for the treatment of adult patients with the rare genetic disorder, acute hepatic porphyria.
Authorisation has been granted in the UK for the STEADFAST clinical study of TX200, which is the first-in-human trial to evaluate a CAR-Treg cell therapy.
A Phase III study of oral relugolix has met its primary efficacy endpoint in men with advanced prostate cancer, supporting a New Drug Application submission to the FDA.